Home > Expanded Access > An Intermediate Access Protocol for Selumetinib for Treatment of Neurofibromatosis Type 1

AstraZeneca

An Intermediate Access Protocol for Selumetinib for Treatment of Neurofibromatosis Type 1

Official Title: 
An Intermediate Access Protocol for Selumetinib for Treatment of Neurofibromatosis Type 1 With Inoperable, Progressive/Symptomatic Plexiform Neurofibromas (PN)
Brief Summary: 
This will be an open-label, single-arm, multicenter intermediate access protocol which provides treatment access to selumetinib for eligible patients with neurofibromatosis type 1 (NF1) who have inoperable, progressive/symptomatic plexiform neurofibromas (PN) without any alternative therapeutic options. All patients will continue to receive drug while they are deriving clinical benefit . Approximately 100 patients in the US will be treated as part of this protocol
Detailed Description: 

Patients must have received a clinical diagnosis of NF1 and have inoperable, progressive/symptomatic PN, where inoperable is defined as PN that cannot be surgically completely removed without risk of substantial morbidity.

The population are patients with NF1 who have inoperable, progressive/symptomatic PN aged ≥ 2years with onset of disease before they were 18 years and who have demonstrated an ability to swallow whole capsules, who have no further treatment options and are not eligible for clinical trials.

There is no maximum duration for selumetinib treatment. Patients may continue to receive selumetinib as long as they continue to show clinical benefit, as judged by the treating physician, and in the absence of unacceptable toxicity.

Once patients have been discontinued from treatment, other available treatment options will be at the discretion of the physician

Available
EA Type
Intermediate-size Population
NF type1 With Inoperable Plexiform Neurofibromas

Drug: Selumetinib
open-label, single-arm, multicenter intermediate access protocol

Eligibility Criteria: 

Inclusion Criteria:

1. Diagnosis of neurofibromatosis type 1 (NF1) and have inoperable, progressive/symptomatic plexiform neurofibromas (PN)

2. Presence of inoperable PN , defined as a PN that cannot be surgically completely removed without risk for substantial morbidity

3. Patients aged ≥2 with onset of disease before they were 18 years and a BSA ≥ 0.55 m2 who are able to swallow whole capsules. (approx. length 15.4 mm, diameter 5.4 mm). A swallow test must be performed before requesting drug

4. Normal cardiac function defined as normal ejection fraction (ECHO, MUGA or cardiac MRI) as per institutional normal and absence of prior heart disease

5. Adequate blood pressure as defined in line with local practice.

6. The patient has exhausted all available approved therapies as appropriate for NF1 with inoperable progressive/symptomatic PN

7. Provision of a signed informed consent prior to any protocol specific procedures. Patients already receiving selumetinib through single patient access who enroll in this protocol must be reconsented and sign the consent form for this intermediate access protocol.

8. For female patients of childbearing potential, have evidence of a post-menopausal status, or a negative urinary or serum pregnancy test.

Exclusion Criteria:

1. Unresolved chronic toxicity ≥ CTCAE Grade 2 from previous therapy

2. Patients eligible for any ongoing clinical trials with selumetinib in the indication in question

3. Ophthalmological conditions: Current or past history of retinal pigment epithelial detachment (RPED)/central serous retinopathy (CSR) or retinal vein occlusion Intraocular pressure (IOP) should not be > 21 mmHg for adults or outside the range of normal for children or uncontrolled glaucoma (irrespective of IOP)

4. Male or female patients of reproductive potential and, as judged by the investigator, are not employing an effective method of birth control.

5. Female patients who are breast-feeding.

6. Have evidence of any other significant clinical disorder or laboratory finding that, as judged by the treating physician, makes it undesirable for the patient to participate in the study.

7. Have any evidence of a severe or uncontrolled systemic disease (e.g. unstable or uncompensated respiratory, cardiac, hepatic, or renal disease, active infection (including hepatitis B, hepatitis C, HIV), active bleeding diatheses or renal transplant

8. Have refractory nausea and vomiting, chronic gastrointestinal diseases (e.g., inflammatory bowel disease), or significant bowel resection that would adversely affect the absorption / bioavailability of the orally administered study medication

Eligibility Gender: 
All
Eligibility Age: 
Minimum: 2 Years
Countries: 
United States
Locations: 

Children's of Alabama
Birmingham, Alabama, 35233

Kaiser Permanente Oakland Medical Center
Oakland, California, 94611

Presbyterian/St. Luke's Medical Center
Denver, Colorado, 80218

Alfred I. DuPont Hospital for Children
Wilmington, Delaware, 19803

Children's National Medical Center
Washington, District of Columbia, 20010

St. Luke's Health System
Boise, Idaho, 83712

Lurie Children's Hospital
Chicago, Illinois, 60611

Indiana University Health
Indianapolis, Indiana, 46202

Our Lady of the Lake - St. Jude Affiliate Clinic
Baton Rouge, Louisiana, 70808

Ochsner Medical Center
New Orleans, Louisiana, 70121

Willis-Knight Cancer Center
Shreveport, Louisiana, 71103

National Institute of Health
Bethesda, Maryland, 20892

Tufts Medical Center
Boston, Massachusetts, 02111

Michigan Medicine
Ann Arbor, Michigan, 48109

Spectrum Health
Grand Rapids, Michigan, 49503

Children's Minnesota
Minneapolis, Minnesota, 55404

SSM Cardinal Glennon Children's Hospital
Saint Louis, Missouri, 63104

Albany Medical Center
Albany, New York, 12208

Memorial Sloan Kettering
New York, New York, 10065

Duke University
Durham, North Carolina, 27710

University Hospitals Cleveland Medical Center
Cleveland, Ohio, 44106

Jimmy Everest Cancer Center
Oklahoma City, Oklahoma, 73104

The Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, 19104

St Jude Children's Research Hospital
Memphis, Tennessee, 38105

Dell Children's Medical Center
Austin, Texas, 78723

Texas Children's Hospital
Houston, Texas, 77030

Children's Hospital of San Antonio
San Antonio, Texas, 78207

University of Utah
Salt Lake City, Utah, 84112

Children's Hospital of Wisconsin
Milwaukee, Wisconsin, 53226

Contacts: 

AstraZeneca Clinical Study Information Center
1-877-240-9479
information.center@astrazeneca.com

Medicine Access Clinigen Group
medicineaccess@clinigengroup.com

Miriam Bornhorst, MD
Principal Investigator
Investigator

AstraZeneca
EA Number: 
Keywords: 
Neurofibromatosis type1, Plexiform Neurofibromas, inoperable, progressive/symptomatic plexiform neurofibromas (PN) without any alternative therapeutic options, mutation in the NF1 gene, Selumetinib, Early Access, Intermediate Access Protocol
MeSH Terms: 
Neurofibromatoses, Neurofibromatosis 1, Neurofibroma, Neurofibroma, Plexiform
Disclaimer:
Expanded Access program information for companies listed in the Expanded Access Company Directory is pulled daily from ClinicalTrials.gov, a resource provided by the National Institutes of Health in cooperation with the U.S. Food and Drug Administration. Click here for more information about ClinicalTrials.gov.